

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Incorporated in the People's Republic of China)
(Company Registration No.: 91120000103100784F)

ESTIMATED RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

IMPORTANT REMINDER

- This announcement on estimated results applies to situations where a listed company anticipates profitability for the relevant financial period, with its net profit estimated to decrease by 50% or more compared to the corresponding period of the immediately preceding financial year¹.
- It is estimated that the net profit attributable to equity holders of the parent for the six (6) months ended 30 June 2026 (“1H FY2026”) will range from approximately RMB620 million to RMB660 million. This represents a decrease of approximately RMB1,307.62 million to RMB1,267.62 million compared to the corresponding period ended 30 June 2025 (“1H FY2025”), reflecting a year-on-year decrease of approximately 68% to 66%.
- It is estimated that the net profit attributable to equity holders of the parent (after deducting non-recurring gains or losses) for 1H FY2026 will range from approximately RMB610 million to RMB650 million. This represents an increase of approximately RMB13.76 million to RMB53.76 million compared to 1H FY2025, reflecting a year-on-year increase of approximately 2% to 9%.

1. Estimated Results for the Reporting Period

(a) Reporting Period

1 January 2026 to 30 June 2026.

(b) Estimated Results

Based on a preliminary assessment by the finance department of the Company:

- (i) the net profit attributable to equity holders of the parent for 1H FY2026 is estimated to range from approximately RMB620 million to RMB660 million, representing a decrease of approximately RMB1,307.62 million to RMB1,267.62 million compared to 1H FY2025, reflecting a year-on-year decrease of approximately 68% to 66%; and

¹ Pursuant to Rule 5.1.1 of the prevailing *Listing Rules of the Shanghai Stock Exchange* (《上海证券交易所股票上市规则》), where a listed company anticipates profitability for the half-year period, with its net profit estimated to increase or decrease by 50% or more compared to the corresponding period of the immediately preceding financial year, the company shall publish an announcement on its estimated results for the half-year period within fifteen (15) days after the end of the period.

- (ii) the net profit attributable to equity holders of the parent (after deducting non-recurring gains or losses) for 1H FY2026 is estimated to range from approximately RMB610 million to RMB650 million, representing an increase of approximately RMB13.76 million to RMB53.76 million compared to 1H FY2025, reflecting a year-on-year increase of approximately 2% to 9%.

- (c) The estimated results for the reporting period set out above have not been audited by any certified public accounting firm.

2. Operating Results and Financial Performance for the Corresponding Period of the Immediately Preceding Financial Year

- (a) The total profit before tax for 1H FY2025 was RMB2,267,022,700. The net profit attributable to equity holders of the parent for 1H FY2025 was RMB1,927,623,000 and the net profit attributable to equity holders of the parent (after deducting non-recurring gains or losses) for 1H FY2025 was RMB596,244,000.

- (b) The earnings per ordinary share for 1H FY2025 was RMB2.50.

3. Main Reason(s) for the Estimated Decline in Performance for the Reporting Period

The estimated year-on-year decrease in net profit attributable to equity holders of the parent was mainly due to the absence, during the current reporting period, of the non-recurring gain recognised in 1H FY2025 from the Company's disposal of its remaining 12% equity interest in Tianjin TSKF Pharmaceutical Co., Ltd. (中美天津史克制药有限公司), which was then an associated company of the Company, to Haleon China Co., Ltd. and Haleon CH SARL. The disposal resulted in a disposal gain of approximately RMB1.54 billion, with an after-tax net profit of approximately RMB1.31 billion.

4. Risk Warning

The estimated results set out in this announcement are based on a preliminary assessment conducted by the finance department of the Company using its professional judgment and have not been audited by any certified public accounting firm. As at the date of this announcement, the Company is not aware of any material uncertainties that may affect the accuracy of the estimated results contained in this announcement.

5. Other Matters

The information contained in this announcement is based on preliminary estimates. As such, the actual financial results for 1H FY2026 may differ from those disclosed in this announcement. Shareholders and potential investors of the Company are advised to refer to the interim financial statements for 1H FY2026, which will be announced in due course.

Shareholders and potential investors are reminded to exercise caution when dealing in the shares of the Company.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
14 July 2026